⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PTCT News
PTC Therapeutics, Inc.
Form 8-K
sec.gov
PTCT
PTC Therapeutics to Participate in Upcoming Investor Conferences
prnewswire.com
PTCT
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
prnewswire.com
PTCT
Form 8-K
sec.gov
PTCT
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
prnewswire.com
PTCT
Form 8-K
sec.gov
PTCT
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
prnewswire.com
PTCT
Hamilton Lane Board Elects Michael Schmertzler as New Independent Director
prnewswire.com
PTCT
HLNE
Form 8-K
sec.gov
PTCT
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
PTCT